OUR VISION

Our ‘Vision’  is  to position Envision Sciences as a leading oncology diagnostic, prognostic and companion diagnostic company. Our novel biomarker discovery program will also define new targets for specific therapeutic intervention in cancer patients.

OUR GOALS

Envision’s primary ‘Goals’ are:

• to provide new industry standards in diagnostics, prognostics and companion diagnostics for a range of cancers, enabling healthcare service providers to achieve better patient outcomes
• to provide game changing diagnostics, prognostics and companion diagnostics for cancers with unmet needs; specifically those with very poor prognosis and often referred to in lay terms as the ‘killer’ cancers

THERAPEUTIC TARGETS

Envision’s approach for interaction with diagnostic and therapeutic provider companies:

• early engagement with stakeholders to develop innovative collaboration models for patient access to our technology, and to create win-win business solutions for our partners
• the provision of viable therapeutic targets for multiple cancers and to co-operatively develop novel strategies for effective cancer treatment and patient management

PETER PURSEY AM
Executive Chairman / Chief Executive Officer

Peter has led a range of teams in his career and is an experienced leader and strategic planner. He has led the development and strategic direction of the therapeutics company PresSura Neuro for over 5 years and brings all the experience of development, clinical trials and an expertise in international industry science networks to Envision. He is experienced at capital raising across a number of industries in Australia and overseas, and his skill sets are well suited to lead the development and commercial goals set for Envision.

Peter is an experienced public company executive and has held director positions in various companies and industry sectors including in energy, mining services and medical therapeutics. His recent appointments include being chairman of PresSura Neuro (therapeutics for traumatic brain injury and concussion), executive chairman of Austin Engineering (ASX Code:ANG) in 2016. Peter co-founded Envision in 2016. 

Email: info@envisionsciences.com

JOHN HIGGINS AO
Non Executive Director

John is an experienced businessman with extensive experience in the international business environment. He holds chair and director appointments across a number of business industry sectors in Australia and overseas.

CHARLES T. TODD Jr
Senior Vice President US Operations

Charles joins Envision Sciences with over 30 years in C Suite positions across the diagnostic and pharmaceutical industries.

He was the founder and CEO of GenCare Biomedical Research Corporation, the first dedicated Oncology laboratory in the United States. He sold this laboratory to BioReference Laboratories in 1995 where he was responsible for organic revenue growth of more than one billion dollars over 22 years.

His major accomplishments include developing and implementing industry leading programs in the areas of Oncology, Women’s Health and Genetics, with an emphasis on prostate, colon and ovarian cancers.  Charles was responsible for sales and marketing activities of OPKO Health’s 4K Score test after their acquisition of BioReference Laboratories in 2014  (NYSE – “OPK”).

Dr KAPIL DHINGRA
Board Advisor

Dr Dhingra was appointed as Corporate and Strategic R&D advisor in 2020. He was Head of the Oncology Leadership Team and Head of Oncology Clinical Development at Roche for 9 years. Prior to that he held senior physician appointments with Eli Lilly and Company and the MD Anderson Cancer Centre.

Kapil has been directly involved as a board member in multi-billion-dollar acquisitions by major pharmaceutical companies in radioligand and diagnostics in oncology especially prostate cancer. Kapil was a director of Exosome Diagnostics for 5 years before it was acquired for $575M. Exosome Dx develops urine based genomic early detection tests for prostate cancer.